OnKure Therapeutics, Inc.OKUR

OnKure Therapeutics Inc. lost $15.2 million in the quarter to 31 March 2026, according to its 10-Q, while burning $12.9 million in operating cash and posting a headline diluted loss of $1.11 per share on 13.7 million shares. The balance sheet still sports $192.1 million of cash and $184.4 million of shareholders’ equity, so the company isn’t staring at the abyss-yet-but it is sending invoices to the same bank account that keeps rejecting them. (source: 10-Q, https://www.sec.gov/Archives/edgar/data/1637715/000119312526206345/okur-20260331.htm)

The company markets itself as a precision-medicine outfit that designs small-molecule drugs to snipe specific cancer mutations, and its website features scientists in spotless coats peering into microscopes while the PI3Kα franchise is described as “best-in-class.” The trouble is, the PI3Kα programme is still in the clinic and the website’s “clinical pipeline” page shows only a candidate list and a microscope slide; it proves intent, not efficacy. (source: OnKure Therapeutics Clinical Pipeline, https://onkuretherapeutics.com/pipeline/; PI3K page, https://onkuretherapeutics.com/pipeline/pi3k/)

Filings confirm that OnKure entered a $150 million private placement in November 2025, touted as “oversubscribed,” only to lock itself out of the ATM market until September 2026 under a 180-day restriction tied to the PIPE purchase. In other words, the money is spoken for but the shares are not sold, which makes the “oversubscribed” label look less like investor demand and more like a polite fiction to keep the share price from gaping open on Monday morning. (source: 10-Q, https://www.sec.gov/Archives/edgar/data/1637715/000119312526206345/okur-20260331.htm)

Inside the numbers, R&D spend was $11.7 million for the quarter, capex was a rounding error at $5,000, and liabilities sat at $14.3 million against total assets of $198.7 million. The cash and equivalents line at $192.1 million is the one clean figure in the set, but the operating cash-flow burn of $12.9 million means the company is haemorrhaging more than the yield on a high-return savings account. (source: 10-Q, https://www.sec.gov/Archives/edgar/data/1637715/000119312526206345/okur-20260331.htm)

For a stock that trades on promise rather than product, the public narrative is all clinical milestones and precision jargon, while the ledger quietly records red ink. The company’s Form 4s on 8 and 24 June 2026 show insiders buying small lots of shares before the blackout window, behaviour that looks less like conviction and more like price support ahead of a quiet period. The gap between the polished pitch deck and the 10-Q is now wide enough to park a Phase I trial. (source: Form 4 - 2026-06-08, https://www.sec.gov/Archives/edgar/data/1637715/000188971626000001/xslF345X06/form4-06082026_100613.xml; Form 4 - 2026-06-24, https://www.sec.gov/Archives/edgar/data/1637715/000160928426000003/xslF345X06/form4-06242026_110612.xml)

If you want to see the story in one image, visit OnKure’s pipeline page and look at the scientist holding the microscope slide: it’s the same stock photograph used for every precision-medicine start-up from Cambridge to Cambridge, Massachusetts. The picture proves nothing about the science; it only proves the company has a photographer. (source: OnKure Therapeutics Clinical Pipeline image, https://onkuretherapeutics.com/wp-content/uploads/bg-parallax-header-slide-min-1536x864.jpg)

The filing trail is complete and consistent, but the trail leads to a single conclusion: OnKure is a pre-revenue biotech with a clean balance sheet and a messy income statement. Until the PI3Kα programme yields data that investors can price, the stock will trade on narrative, not numbers, and the numbers currently favour the shorts. (source: SEC EDGAR index for CIK 1637715, https://www.sec.gov/edgar/browse/?CIK=1637715)